An observational study in Anti-MAG Neuropathy, Peripheral Nervous System Disease and Anti-Myelin-Associated Glycoprotein Antibodie, sponsored by Centre Hospitalier Universitaire de Nice. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Centre Hospitalier Universitaire de Nice · Observational
Among 31 studies in Peripheral Nervous System Diseases with a site in France — 7 open to participants now, 9 under way, 2 of them phase 3. Peripheral Nervous System Diseases · France.
Among the 31 studies in Peripheral Nervous System Diseases with a site in France, this one is one of 3 that started in 2026, is one of 5 observational ones, and was the 31st registered.
476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.
Browse Peripheral Nervous System Diseases studies →7 of the 31 studies in Peripheral Nervous System Diseases with a site in France are open now. Recruiting first, the newest first:
Institut pour la Pratique et l'Innovation en PSYchologie appliquée (Institut Pi-Psy) · Sites in France
Centre Antoine Lacassagne · Sites in France
Saint-Gregoire Private Hospital Center · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Centre Hospitalier de Cornouaille · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 65 Peripheral Nervous System Diseases studies recruiting now, 44 (68%) set no upper age limit and 10 (15%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 7 · Phase 4 1
First in 2004; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 100 is above the median of 80 across 97 observational studies indexed under Peripheral Nervous System Diseases.
Median enrollment 45 across the 26 interventional studies, 60 across the 5 observational. Of the 20 that completed or were terminated, 7 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 31 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nice is the lead sponsor of 723 studies on the registry; 176 are open to participants now.
Centre Hospitalier Universitaire de Nice has 1 study filed under Peripheral Nervous System Diseases — fewer than ten, so there is no comparison to draw.
5 of the studies in Peripheral Nervous System Diseases with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07661667Centre Hospitalier de CornouailleThis Study Aims to Investigate the Efficacy of Photobiomodulation in the Treatment of Anti-MAG-induced Peripheral Neuropathy (LASER-MAG) | 2026-12 |
| NCT06400849Centre Antoine LacassagneComparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy | 2026-12-04 |
| NCT06964243Institut pour la Pratique et l'Innovation en PSYchologie appliquée (Institut Pi-Psy)Protocol Assessment of Motor Cortex rTMS for Treating Neuropathic Pain | 2026-12-19 |
| NCT07591779University Hospital, LimogesPhysical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment | 2027-04-15 |
| NCT03881930Assistance Publique - Hôpitaux de ParisBalance Rehabilitation With Modified Visual Input in Patients With Neuropathy | 2027-06-01 |
Among the 31 studies in Peripheral Nervous System Diseases with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
"Anti-myelin-associated glycoprotein (anti-MAG) neuropathy is a rare dysimmune peripheral neuropathy, most commonly associated with an IgM monoclonal gammopathy. Its course is generally slow but may lead to significant functional disability. Despite therapeutic advances, including rituximab, intravenous immunoglobulins (IVIg), immunochemotherapy, and more recently Bruton tyrosine kinase inhibitors (BTKi), treatment response remains highly variable between patients. The Terminal Latency Index (TLI), an electrophysiological parameter reflecting distal demyelination, is a recognized diagnostic marker of anti-MAG neuropathy. However, its potential role as a predictive biomarker of treatment response remains insufficiently studied. Identifying a simple, reproducible, and readily available biomarker that could predict treatment response would be of major clinical importance for personalized patient management and optimization of therapeutic strategies. This monocentric retrospective study will analyze clinical, biological, and electrophysiological data from patients with anti-MAG neuropathy followed at Nice University Hospital (CHU de Nice) to assess the predictive value of baseline TLI for clinical response 12 months after treatment initiation."
"Adult patients with documented anti-MAG activity-associated neuropathy, followed at the Reference Center for Rare Diseases of the Peripheral Nervous System at Nice University Hospital (CHU de Nice) between January 2005 and July 2025. Planned number of participants: 100 patients."
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This monocentric retrospective observational study will include 100 patients with anti-myelin-associated glycoprotein (anti-MAG) neuropathy followed at Nice University Hospital (CHU de Nice). No additional intervention or modification of routine clinical care will be performed. Clinical, biological, therapeutic, and electrophysiological data will be retrospectively collected from medical records and available archives. Routinely performed electroneuromyography (ENMG) data will be analyzed, with particular emphasis on the Terminal Latency Index (TLI), calculated from available electrophysiological parameters according to the standard formula. The predictive value of baseline TLI for clinical response to treatment at 12 months will be assessed. Treatments received as part of routine care, including rituximab, IVIg, immunochemotherapy, and Bruton tyrosine kinase inhibitors (BTKi), will be recorded. No treatment will be assigned or modified by the study. Data will be pseudonymized and ent
Diagnostic Test: Electroneuromyography (ENMG) and Terminal Latency Index (TLI) Assessment
This monocentric retrospective observational study will include 100 patients with anti-myelin-associated glycoprotein (anti-MAG) neuropathy followed at Nice University Hospital (CHU de Nice). No additional intervention or modification of routine clinical care will be performed. Clinical, biological, therapeutic, and electrophysiological data will be retrospectively collected from medical records and available archives. Routinely performed electroneuromyography (ENMG) data will be analyzed, with particular emphasis on the Terminal Latency Index (TLI), calculated from available electrophysiological parameters according to the standard formula. The predictive value of baseline TLI for clinical response to treatment at 12 months will be assessed. Treatments received as part of routine care, including rituximab, IVIg, immunochemotherapy, and Bruton tyrosine kinase inhibitors (BTKi), will be recorded. No treatment will be assigned or modified by the study. Data will be pseudonymized and ente
Favorable Clinical Response at 12 Months (≥1-Point Decrease in INCAT Score)
Clinical response at 12 months, defined as a reduction of at least 1 point in the INCAT disability score from baseline. This outcome will be used to assess the predictive value of the baseline Terminal Latency Index (TLI) for treatment response in patients with anti-MAG neuropathy.
Time frame: 12 months after treatment initiation
Predictive performance of TLI according to treatment strategy
Assessment of the predictive performance of baseline TLI for clinical response at 12 months, stratified according to the treatment strategy received.
Time frame: 12 months after treatment initiation.
Correlation between TLI, anti-MAG antibody titer, and INCAT score evolution
Assessment of the association between baseline TLI, quantitative anti-MAG antibody titer, and change in the INCAT disability score from baseline to 12 months.
Time frame: Baseline to 12 months after treatment initiation
Optimal TLI threshold for predicting treatment response
Determination of the optimal baseline TLI threshold for predicting clinical response at 12 months using Receiver Operating Characteristic (ROC) curve analysis and the Youden index
Time frame: Baseline to 12 months after treatment initiation
Start is estimated for Sep 2026; primary completion for Sep 2026, 0 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peripheral Nervous System Diseases →
Centre Hospitalier Universitaire de Nice →